FiercePharmaOriginal article
{"a":[{"_":"Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma","$":{"href":"/pharma/roche-lunsumio-delivers-positive-confirmatory-trial-readout-follicular-lymphoma","hreflang":"en"}}]}
Phase 3positiveLunsumioPositive
AI Analysis
Summary
Roche's Lunsumio met its primary endpoint in a Phase 3 trial for earlier-line follicular lymphoma, advancing the company's T-cell engager portfolio.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint in earlier-line follicular lymphoma
Importance:7/10
Sentiment:
0.80
T-cell engageroncologylymphomaPhase 3clinical trial
Related Companies
Read the original article
Published by FiercePharma on September 17, 2026 10:26 AM